340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
President Joe Biden has written an op-ed for The Wall Street Journal detailing his plan to fight inflation.
Well, perhaps the word "detailing" is too generous. The preponderance of the column features Biden taking credit for economic growth that can be attributed to the reopening of the economy that was shuttered by the governing class during COVID. Biden, of course, not only championed those closings but was critical of Republican governors who opened their states before he deemed it appropriate.
But with midterms approaching, there's been a concerted effort underway to exonerate the…
